



Zykadia[®] (ceritinib) – Expanded indication

- On May 26, 2017, [Novartis announced](#) the FDA approval of [Zykadia \(ceritinib\)](#) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
 - Previously, Zykadia was approved for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to [Xalkori[®] \(crizotinib\)](#).
- The expanded indication for Zykadia was approved based on the open-label ASCEND-4 study that enrolled 376 patients with ALK-positive NSCLC who had not received prior systemic therapy for metastatic disease. Patients were randomized to Zykadia or chemotherapy plus maintenance chemotherapy. The major efficacy outcome measure was progression-free survival (PFS).
 - The PFS was 16.6 months for Zykadia patients vs. 8.1 months for chemotherapy treated patients (Hazard ratio = 0.55; 95% CI: 0.42, 0.73; p < 0.001).
 - The overall response rate was 73% (95% CI: 66, 79) for Zykadia patients vs. 27% (95% CI: 21, 34) for chemotherapy treated patients.
 - The duration of response was 23.9 months (95% CI: 16.6, not estimable) for Zykadia patients vs. 11.1 months (95% CI: 7.8, 16.4) for chemotherapy treated patients.
- The recommended dose of Zykadia is 750 mg orally once daily until disease progression or unacceptable toxicity.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.